Pfizer's COVID-19 Pill Paxlovid Underutilized in Nursing Homes Despite Proven Efficacy
Portfolio Pulse from Vandana Singh
A study conducted by researchers at the University of Rochester and Harvard University revealed that Pfizer's COVID-19 pill, Paxlovid, was underutilized in nursing homes, despite its proven efficacy. The study found that only about 25% of nursing home residents with COVID-19 were prescribed any antiviral medication from May 2021 to December 2022. The underuse of Paxlovid likely led to a significant amount of avoidable mortality, according to Harvard professor Michael Barnett.

July 14, 2023 | 6:40 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Pfizer's COVID-19 pill, Paxlovid, was underutilized in nursing homes, despite its proven efficacy. This underutilization could potentially impact Pfizer's revenues from the sale of Paxlovid.
The underutilization of Pfizer's Paxlovid in nursing homes, despite its proven efficacy, could potentially impact the company's revenues from the sale of the drug. However, the overall impact on Pfizer's stock price is uncertain as the company has a diverse portfolio of products and the revenue from Paxlovid is just a part of it.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100